top of page

Capstan Therapeutics' Laura Shawver on 'decorating' LNPs with antibodies

Dr. Shawver describes how Capstan plans to achieve in-vivo CAR-T by utilizing LNPs to deliver mRNA to lymphocytes in the body.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page